The use of oncolytic viruses in selected tumours
More details
Hide details
Departament of Virology, Medical University of Lublin, Poland
J Pre Clin Clin Res. 2013;7(2):98–103
Neoplastic diseases are the leading cause of death among adults. Despite significant advances in pharmacotherapy, advanced radiotherapy and high level of oncology surgery still the effects of a treatment are too low. Doctors are trying to find new, effective methods to cure people suffering from cancer. The big hope for a breakthrough in the treatment of cancers is put in a oncolytic viruses therapy. Innovative approach to viruses, that are usually associated with a potential risk to health, gives a chance for a breakthrough in oncology. This article is an overview of studies that have used different oncolytic viruses. : :

State of knowledge:
Currently is doing a lot of research on the use of viruses in oncology. The mechanism of action of this method is to infect the tumour cells by the virus, replicating inside them and their lysis during the release of new virions. Additional advantages is the possibility to use in many types of cancer and regardless of clinical stage. Furthermore virotherapy may be combined with standard methods for achieving greater results.

The results of these studies demonstrate the high effectiveness of this therapy. A large force action is combined with low side-effects and the ability to connect it with other therapies.

Alemany R. Viruses in cancer treatment. Clin Transl Oncol. 2013;15(3): 182–188.
Mullen T, Tanabe K. Viral oncolysis. The Oncol. 2002; 7: 1–6: 119.
Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev. 2010; 21(2–3): 127–134.
Singh PK, Doley J, Kumar GR, Sahoo AP, Tiwari AK. Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res. 2012;136(4): 571–584.
Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD.Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res. 2011; 17(13): 4214–4224.
Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, Ali A. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 2012; 18(4): 771–781.
Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol. 2012; 13(9): 1750–1760.
Rusin P, Markiewicz Ł, Majsterek I. Uwarunkowania genetyczne nowotworów głowy i szyi. Post Hig Med Dosw. 2008; 62: 490–501.
Lane DP. p53, guardian of the genome. Nature (Lond). 1992; 358: 15–16.
Levine AJ. p53 the cellular gatekeeper for growth and division. Cell. 1997; 88: 323–331.
Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancer. Science (Washington DC). 1991; 49: 49–53.
Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R i wsp. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000; 6: 798–806.
Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T i wsp. Selective replication and oncolysis in p53 mutant tumors with ONYX 015, an E1B-55 kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 2000; 60: 6359 6366.
Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E I wsp. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001; 19: 289–298.
Morley S, MacDonald G, Kirn D, Kaye S, Brown R, Soutar D i wsp. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res. 2004; 10: 4357–4362.
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L i wsp. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6: 879–885.
Wong HH, Lemoine NR, Wang Y. Oncolytic Viruses for Cancer Therapy:Overcoming the Obstacles.Viruses. 2010; 2(1): 78–106.
Yuan ZY, Zhang L, Li S, Qian XZ, Guan ZZ. Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer. Ai Zheng. 2003; 22: 310–313.
Xu RH, Yuan ZY, Guan ZZ, Cao Y, Wang HQ, Hu XH i wsp. Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer. Ai Zheng. 2003; 22: 1307–1310.
Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot Phase II clinical trial. W J Gastroenterol. 2004; 10: 3634–3638.
Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW i wsp. Phase III randomized clinical trial of intratumoralinjection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004; 23: 1666–1670.
Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J i wsp. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colonystimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009; 8(8): 676–682.
Kowalska A, Kowalik A. Telomer i telomeraza w onkogenezie. Współcz. Onkol. 2006; 10(10): 485–496.
Wodarz D, Hofacre A, Lau JW, Sun Z, Fan H, Komarova NL. Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PloS Comput Biol. 2012; 8(6): e1002547.
Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T i wsp. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 2006; 126: 1115–1117.
Mace AT, Harrow SJ, Ganly I, Brown SM. Cytotoxic effects of the oncolytic herpes simplex virus HSV 1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007; 127: 880–887.
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ i wsp. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colonystimulating factor. Clinical Cancer Research. 2006; 12(22): 6737–674
Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ. Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther. 2012; 12: 1669–1678.
Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D i wsp. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck. 2011; 33(10): 1394–1399.
DeAmbrosis K, De’Ambrosis B. Nonmelanoma skin cancer with perineural invasion: report of outcomes of a case series. Dermatol Surg. 2010;36(1):133–138.
Mueller CS, Reichrath J. Histology of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol. 2008; 624: 215–226.
32. Salimi V, Tavakoli-Yaraki M, Mahmoodi M, Shahabi S, Gharagozlou M, Shokri F, Mokhtari-Azad T. The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. Iran Red Crescent Med J. 2013 January; 15(1): 62–67..
Echchgadda I, Kota S, DeLa Cruz I, Sabbah A, Chang T, Harnack R, et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 2009; 16(12): 923–35.
Echchgadda I, Kota S, DeLa Cruz I, Sabbah A, Chang T, Harnack R, et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 2009; 16(12): 923–935
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6): 1264–1273.
Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. Journal Of Clinical Investigation. 1993; 91: 2837–2843.
Tae-Jin Song D Eisenberg P Adusumilli M Hezel Y Fong. Oncolytic Herpes Viral Therapy is Effective in the Treatment of Hepatocellular Carcinoma Cell Line J. Gastrointest Surg. 2006; 10(4): 532–542.
K Parato C J Breitbach F Le Boeuf J Wang Ch Storbeck C Ilkow et al. The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers Mol Ther. 2012; 20(4): 749–758.
J Heo C J Breitbach A M Chang W Kim R Patt M K Kim Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy Mol Ther. 2011; 19(6): 1170– 1179
Kachuri L, De P, Ellison LF, Semenciw R. Cancer incidence, mortality and survival trends in Canada,1970–2007. Chronic Dis Inj Can. 2013; 33(2): 69–80.
Paliwal P, Arora D, Mishra AK. Epithelial mesenchymal transition in urothelial carcinoma: twist in the tale. Indian J Pathol Microbiol. 2012; 55(4): 443–449.
Matteo Fassan, Edouard J Trabulsi, Leonard G Gomella, Raffaele Baffa Targeted therapies in the management of metastatic bladder cancer. Biologics. 2007; 1(4): 393–406.
Hanel EG, Xiao Z, Wong KK, LeePW, Britten RA, Moore RB. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol. 2004 Nov;172(5 Pt 1): 2018– 2022.
Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC JR, Mulholland SG, Lattime EC. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001; 166(4): 1291–1295.
Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006; 12(1): 305–313.
Senzer N, Nemunaitis J, Goldstein M, et al. A phase 1 dose-escalation trial of intravesical CG0070 for superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) failure. Molecular Therapy. 2006; 13
Mullen JT, Tanabe KK.Viral oncolysis. Oncologist. 2002; 7(2): 106–119.
Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 2001; 172: 27–36